Nova Biologiques is a private Canadian R&D company dedicated to develop and produce new products based on the expression of recombinant proteins. As a technically-driven business, we are conducting our research through a combination of external collaborations and internal projects. Our key ongoing collaborations include research centers in Asia, more specifically in China.

At Nova Biologiques, recombinant antigens are created by utilizing cells to produce large quantities of viral proteins. Proteins are the most important of all the materials that compose all living organisms. A recombinant protein is a protein that is derived from a recombinant DNA vector. These recombinant proteins can be variety of types such as antibodies, antigens, hormones and enzymes. Advantages of recombinant proteins are that the vector can be chosen to be not only safe but also easy to grow and store, reducing production cost. The recombinant viral antigens, structurally similar as viruses, are used as vaccines to induce a strong immune response leading to protection against the targeted disease. Recombinant vaccines cannot exhibit pathogenicity because they contain only harmless genetic material.

Cell culture technology is becoming an essential part of eukaryotic expression systems. Therefore, in our R&D lab, a high expression platform of genetically engineered animal cells is developed for the commercial production of important proteins.

To support its cell culture vaccine manufacturing expertise, Nova Biologiques is developing convenient and low-cost technologies capable of providing good cell growth and ensuring high yield of recombinant proteins.